摘要
Aurora A kinase (Aurora A) is a serine/threonine kinase regulating control of multiple events during cell-cycle progression. Playing roles in promoting proliferation and inhibiting cell death in cancer cells leads Aurora A to become a target for cancer therapy. It is overexpressed and associated with a poor prognosis in ovarian cancer. Improving cisplatin therapy outcomes remains an important issue for advanced-stage ovarian cancer treatment, and Aurora A inhibitors may improve it. In the present study, we identified natural compounds with higher docking scores than the known Aurora A ligand through structure-based virtual screening, including the natural compound fangchinoline, which has been associated with anticancer activities but not yet investigated in ovarian cancer. The binding and inhibition of Aurora A by fangchinoline were verified using cellular thermal shift and enzyme activity assays. Fangchinoline reduced viability and proliferation in ovarian cancer cell lines. Combination fangchinoline and cisplatin treatment enhanced cisplatin-DNA adduct levels, and the combination index revealed synergistic effects on cell viability. An in vivo study showed that fangchinoline significantly enhanced cisplatin therapeutic effects in OVCAR-3 ovarian cancer-bearing mice. Fangchinoline may inhibit tumor growth and enhance cisplatin therapy in ovarian cancer. This study reveals a novel Aurora A inhibitor, fangchinoline, as a potentially viable adjuvant for ovarian cancer therapy.
学科与关键词
- Natural anthraquinone compound emodin as a novel inhibitor of aurora A kinase: A pilot studyWu, Fen-Lan; Chu, Pei-Yi; Chen, Guan-Yu; Wang, Ke; Hsu, Wei-Yu; Ahmed, Azaj; Ma, Wen-Lung; Cheng, Wei-Chung; Wu, Yang-Chang*; Yang, Juan-Cheng*Chemical Biology and Drug Design, 2022, 99(1): 126-135.被引 7
- Anlotinib induces apoptosis and second growth/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A/p53 pathwayWang, Hongli*; Wang, YuHuman and Experimental Toxicology, 2023, 42: 09603271231185774.被引 1
- SARI 56497, an Exquisitely Selective Inhibitor of Aurora KinasesCarry, Jean-Christophe*; Clerc, Francois; Minoux, Herve; Schio, Laurent; Mauger, Jacques; Nair, Anil; Parmantier, Eric; Le Moigne, Ronan; Delorme, Cecile; Nicolas, Jean-Paul; Krick, Alain; Abecassis, Pierre-Yves; Crocq-Stuerga, Veronique; Pouzieux, Stephanie; Delarbre, Laure; Maignan, Sebastien; Bertrand, Thomas; Bjergarde, Kirsten; Ma, Nina; Lachaud, Sylvette; Guizani, Houlfa; Lebel, Remi; Doerflinger, Gilles; Monget, Sylvie; Perron, Sebastien; Gasse, FrancisJournal of Medicinal Chemistry, 2015, 58(1): 362-375.被引 27
